Enovis Corporation
NYQ: ENOVLive Quote
📈 ZcoreAI Score
Our AI model analyzes Enovis Corporation's price action across multiple timeframes using regression channels and statistical scoring.
Get ENOV Z-Score →About Enovis Corporation
Healthcare
Medical Devices
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
📊 Fundamental Analysis
Enovis Corporation demonstrates a profit margin of -52.7%, which is below the sector average, suggesting competitive pressure.
The company recently reported 2.6% revenue growth, which is modest compared to its industry peers.
Return on Equity (ROE) is -58.3%, which indicates that capital utilization is currently under pressure.
At a current price of $24.42, ENOV currently sits at the 20th percentile of its 52-week range (Range: $21.00 - $37.85).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$1.41B
Trailing P/E
--
Forward P/E
6.16
Beta (5Y)
1.59
52W High
$37.85
52W Low
$21.00
Avg Volume
1.03M
Day High
Day Low